The uptake of the breast cancer drug Trodelvy has also been strong and its approval in additional geographies will further boost sales and advance Gilead’s efforts to diversify in the lucrative oncology space as its leading HIV business faces competition. Trodelvy is approved for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The company is also evaluating the phase III EVOKE-03 study of Trodelvy in combination with Keytruda versus Keytruda monotherapy for patients with first-line PD-L1-high metastatic NSCLC. The results support further investigation of the combination in the first-line metastatic NSCLC.
The median duration of response (DoR) was not reached at the time of data cut-off and the DoR rate at six months was 88% in both cohorts.
Across both cohorts, ORR was 56% and DCR was 82%. Confirmed and unconfirmed ORR was 44% and DCR was 78% in Cohort B (n=32). Results show encouraging activity of Trodelvy in combination with Keytruda in first-line metastatic NSCLC across all PD-L1 subgroups and histologies studied.ĭata showed a confirmed and unconfirmed objective response rate (ORR) of 69% and a disease control rate (DCR) of 86% in Cohort A (n=29). Patients enrolled in Cohorts A or B received the combination of Trodelvy and Keytruda. While Cohort A enrolled patients with squamous/non-squamous NSCLC with a TPS ≥ 50%, Cohort B enrolled patients with squamous/non-squamous NSCLC with a TPS < 50%. Patients were assigned to Cohorts A or B according to tumor proportion score (TPS) status. The phase II EVOKE-02 study is an open-label, global, multi-center, multi-cohort study evaluating Trodelvy in combination with Merck’s MRK Keytruda with or without chemotherapy, regardless of PD-L1 expression, in patients with advanced or metastatic NSCLC without actionable genomic alterations.Īs per the status of the cancer or PD-L1 expression, patients were assigned to cohorts. NSCLC is one of the most common types of lung cancer and currently accounts for up to 85% of diagnoses.
GILD announced encouraging data from the mid-stage study evaluating its breast cancer drug Trodelvy for the treatment of metastatic non-small cell lung cancer (NSCLC).
0 kommentar(er)
